FDA settled a lawsuit by reaching an agreement on a health claim for B vitamins and vascular disease. The agency will allow the following health claim on labels of dietary supplements containing folic acid, vitamin B6, and vitamin B12: As part of a well-balanced diet that is low in saturated fat and cholesterol, folic acid, vitamin B6, and vitamin B12 may reduce the risk of vascular disease.* But the claim must be immediately followed by the following sentence in the same size, type face, and contrast as the first sentence: *FDA evaluated the above claim and found that, while it is known that diets low in saturated fat and cholesterol reduce the risk of heart disease and other vascular diseases, the evidence in support of the above claim is inconclusive. FDA disallowed health claims relating antioxidant vitamins (vitamin C and vitamin E, alone or in combination) to reduced risk of certain kinds of cancer or of individual cancers (cancer of the bladder, breast, cervix, colon, rectum, oral cavity/pharynx, esophagus, lung, prostate, pancreas, skin, and stomach), finding that the scientific evidence against the relationship was greater than that for the relationship.
Ukrainian importers of the Smirnoff brand of vodka overcame counterfeit sales this spring by adding a clear polyvinyl chloride neck shrink sleeve that features an optically variable device (OVD) to ensure product brand identity.
SouthPack ’01 brought packaging manufacturers together from April 24 to 26 at the World Congress Center in Atlanta. The three-day show managed to spark some new technology interests, although many exhibitors were quick to notice the slow pace of attendees throughout the exhibition hall.
The Occupational Safety and Health Administrations comprehensive ergonomics regulations, which would have taken effect in October, were overturned by Congress in a first-time use of the Congressional Review Act of 1996.
The Center for Science in the Public Interest submitted formal petitions to both Food and Drug Administration and the Federal Trade Commission in December to halt labeling and advertising claims that garlic supplements reduce cholesterol by some manufacturers of dietary supplements.
The Food and Drug Administration (FDA) has proposed a 120-day premarket notification for biotech foods in which manufacturers would provide the FDA with information demonstrating that the product is as safe as its conventional counterpart.